UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

~~FORM~~SECURITIES ~~8-K~~AND EXCHANGE COMMISSION

~~CURRENT~~WASHINGTON, ~~REPORT~~D.C. 20549

~~Pursuant~~FORM ~~to Section 13 or 15(d) of the Securities Exchange Act of 1934~~8-K

~~Date~~CURRENT ~~of Report (Date of earliest event reported): September 10, 2025~~REPORT

~~Iterum~~Pursuant ~~Therapeutics~~to ~~plc~~Section 13 or 15(d)

~~(Exact name~~ of ~~Registrant~~the asSecurities ~~Specified~~Exchange inAct ~~Its~~of ~~Charter)~~1934

Ireland	001-38503	Not applicable
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
25 North Wall Quay
Dublin 1, Ireland		Not applicable
(Address of Principal Executive Offices)		(Zip Code)

Date of Report (Date of earliest event reported): October 16, 2025

~~Registrant’s~~Iterum ~~Telephone~~Therapeutics ~~Number, Including Area Code: +353 1 6694820~~plc

(~~Former~~Exact ~~Name~~name orof ~~Former~~Registrant ~~Address,~~as ifSpecified ~~Changed~~in ~~Since~~Its ~~Last Report~~Charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Ireland	001-38503	Not applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

25 North Wall Quay
Dublin 1, Ireland		Not applicable
(Address of Principal Executive Offices)		(Zip Code)

~~☐Written~~Registrant’s ~~communications~~Telephone ~~pursuant~~Number, toIncluding ~~Rule~~Area ~~425~~Code: ~~under~~+353 ~~the~~1 ~~Securities Act (17 CFR 230.425)~~9038354

~~☐Soliciting~~(Former ~~material~~Name ~~pursuant~~or toFormer ~~Rule~~Address, ~~14a-12~~if ~~under~~Changed ~~the~~Since ~~Exchange~~Last ~~Act (17 CFR 240.14a-12~~Report)

~~☐Pre~~Check the appropriate box below if the Form 8-~~commencement~~K ~~communications~~filing ~~pursuant~~is intended to ~~Rule~~simultaneously ~~14d-2(b)~~satisfy ~~under~~the filing obligation of the ~~Exchange~~registrant ~~Act~~under ~~(17~~any ~~CFR~~of ~~240.14d-2(b))~~the following provisions:

☐~~Pre-commencement~~ Written communications pursuant to Rule ~~13e-4(c)~~425 under the ~~Exchange~~Securities Act (17 CFR ~~240~~230.~~13e-4(c~~425))

~~Securities~~☐ ~~registered~~Soliciting material pursuant to ~~Section~~Rule 14a-12~~(b)~~ ofunder the Exchange Act: (17 CFR 240.14a-12)

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.01 per share		ITRM		The Nasdaq Stock Market LLC

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~Indicate~~☐ byPre-commencement ~~check~~communications ~~mark~~pursuant ~~whether~~to ~~the registrant is an emerging growth company as defined in~~ Rule ~~405 of the Securities Act of 1933~~ 13e-4(~~§ 230.405 of this chapter~~c) orunder ~~Rule 12b-2 of~~ the ~~Securities~~ Exchange Act of(17 ~~1934~~CFR (§ 240.~~12b~~13e-~~2 of this chapter~~4(c). )

~~Emerging~~Securities ~~growth~~registered ~~company~~pursuant ☐to Section 12(b) of the Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, par value $0.01 per share	ITRM	The Nasdaq Stock Market LLC

~~Item~~Indicate 5by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.07405 ~~Submission~~of this chapter) or Rule 12b-2 of ~~Matters~~the toSecurities aExchange ~~Vote~~Act of ~~Security~~1934 ~~Holders~~(§ 240.12b-2 of this chapter).

OnEmerging ~~September~~growth 10, 2025, Iterum Therapeutics plc (the "Company") held its 2025 annual general meeting (the “AGM”), at which the Company’s shareholders voted on the following proposals, each of which is described in the Company’s definitive proxy statement (the "Proxy Statement"), filed with the Securities and Exchange Commission on July 28, 2025.company ☐

~~Proposal~~If ~~No.~~an 1:emerging ~~Election~~growth ofcompany, ~~Directors.~~indicate ~~The~~by ~~shareholders~~check ~~elected~~mark ~~David~~if ~~Kelly to~~ the ~~Company’s~~registrant ~~board~~has ofelected ~~directors~~not asto ause ~~Class~~the Iextended ~~director~~transition toperiod ~~serve~~ for acomplying ~~three-year~~with ~~term~~any ~~expiring~~new ator ~~the~~revised ~~Company's~~financial ~~2028~~accounting ~~annual~~standards ~~general~~provided ~~meeting~~pursuant ofto ~~shareholders.~~Section 13(a) ~~The results~~ of the ~~shareholders’~~Exchange ~~vote for the election of Mr~~Act. ~~Kelly were as follows:~~ ☐

Nominee	For	Against	Abstain	Broker Non-Votes
David Kelly	10,795,342	2,848,953	665,812	8,188,446

Item 8.01

Other Events.

~~Proposal No. 2: Ratification of Appointment of~~ At-the Company’s Independent Registered Public Accounting Firm for 2025 and Authorization of the Board of Directors to Approve the Remuneration of the Independent Registered Public Accounting Firm. The shareholders ratified, in a non-~~binding~~Market ~~vote,~~Offering the appointment of KPMG as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2025 and authorized the Company’s board of directors, acting through its audit committee, to set the independent registered public accounting firm’s remuneration. The results of the shareholders’ vote were as follows:

For	Against	Abstain	Broker Non-Votes
17,986,081	3,759,990	752,482	*

On October 16, 2025, Iterum Therapeutics plc (the “Company”) filed with the Securities and Exchange Commission a prospectus supplement (the “Prospectus Supplement”) under the Company’s effective registration statement on Form S-3 (the “Registration Statement”) (File No. 333-284774), relating to the offer and sale of the Company’s ordinary shares, nominal value $0.01 per share, from time to time for additional aggregate gross proceeds of up to $20,000,000 million, not to exceed 21,756,057 ordinary shares (the “Shares”), under its existing at the market offering agreement, dated October 7, 2022 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC, as sales agent.

~~Proposal~~As ~~No.~~of 3:the ~~Advisory~~date ~~vote~~of on the ~~compensation~~Prospectus ofSupplement, the Company’s ~~Named~~previously ~~Executive~~issued ~~Officers~~and sold ordinary shares for an aggregate gross sale proceeds of approximately $36.2 million ~~The~~pursuant ~~shareholders~~to ~~did~~the ~~not~~Sales ~~approve,~~Agreement onand a ~~non-binding~~prior prospectus, ~~advisory~~dated ~~basis~~October 17, ~~the~~2022, ~~compensation~~as ofamended and supplemented by the Company’s ~~named~~prospectus ~~executive~~supplements ~~officers~~dated asOctober 11, ~~disclosed~~2024, inOctober 28, ~~the~~2024, ~~Proxy~~October 30, ~~Statement.~~2024, ~~The~~and ~~results~~a ofprior prospectus supplement, dated December 10, 2024, in each case, under the ~~shareholders~~Company’s ~~vote~~registration ~~were~~statement ason ~~follows:~~Form S-3 (File No. 333-267795).

For	Against	Abstain	Broker Non-Votes
5,406,944	8,449,597	453,566	8,188,446

A&L Goodbody LLP, Irish counsel to the Company, has issued a legal opinion relating to the Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.

~~Proposal~~The ~~No.~~offering 4:of ~~Authorized~~the ~~Share~~Shares ~~Capital~~has ~~Increase~~been ~~Proposal.~~registered ~~The~~pursuant ~~shareholders~~to ~~did~~the ~~not~~Registration ~~approve~~Statement, anand ~~increase~~offerings inof the ~~authorized~~Shares ~~share~~will ~~capital~~be made only by means of the ~~Company~~Prospectus ~~from~~Supplement ~~$1,800,000~~and the accompanying base prospectus. This Current Report on Form 8-K shall not constitute an offer to ~~$2,600,000~~sell byor ~~the~~a ~~creation~~solicitation of an ~~additional~~offer 80to buy the Shares described herein,~~000,000~~ ~~ordinary~~nor ~~shares.~~shall ~~The~~there ~~results~~be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the ~~shareholders’~~securities ~~vote~~law ~~were~~of assuch ~~follows:~~state or jurisdiction.

For	Against	Abstain	Broker Non-Votes
6,512,249	15,836,469	149,835	*

Business Update

~~Proposal No. 5: Directors’ Allotment Authority Proposal.~~ The ~~shareholders~~Company ~~did~~commercially ~~not~~launched ~~approve~~ORLYNVAH™ ~~the~~into ~~grant to~~ the ~~board~~community ofmarket ~~directors~~in ofthe anU.S. ~~updated~~in ~~authority~~August ~~under~~2025 ~~Irish law to allot~~ and ~~issue~~expects ~~shares,~~modest ~~warrants,~~sales ~~convertible~~in ~~instruments~~2025 ~~and~~during ~~options.~~the ~~The~~early ~~results~~stages of ~~the~~its ~~shareholders’~~commercialization ~~vote were as follows:~~efforts.

For	Against	Abstain	Broker Non-Votes
6,564,664	15,390,584	543,305	*

Cautionary Note Regarding Forward-looking Statements

~~Proposal~~This NoCurrent Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. 6:These ~~Pre~~forward-~~emption~~looking ~~Rights~~statements ~~Opt~~include, without limitation, statements regarding the Company’s expectations for ORLYNVAH™ sales in 2025. In some cases, forward-~~out~~looking ~~Proposal~~statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “would,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. ~~The~~Forward-looking ~~shareholders~~statements ~~did~~involve ~~not~~known ~~approve~~and unknown risks, uncertainties and other factors that may cause the ~~grant~~Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the ~~board~~forward-looking ofstatements. ~~directors~~Forward-looking ofstatements aninclude ~~updated~~all ~~authority~~matters ~~under~~that ~~Irish~~are ~~law~~not historical facts. Actual future results may be materially different from what is expected due to ~~issue~~factors ~~shares~~largely (outside the Company’s control, including ~~rights~~the Company’s successful commercialization of ORLYNVAH™ in the U.S. with its commercial partner, EVERSANA, including the Company’s ability to ~~acquire~~maintain ~~shares)~~and continue to build a sales force for ~~cash~~the ~~without~~commercialization ~~first~~of ~~offering~~ORLYNVAH™ ~~those~~in ~~shares~~the U.S. and the Company’s ability to ~~existing~~raise ~~shareholders~~funds to continue to support its operations and other factors discussed under ~~pre~~the caption “Risk Factors” in its Quarterly Report on Form 10-~~emptive~~Q ~~rights~~for ~~that~~the ~~would~~quarterly ~~otherwise~~period ~~apply~~ended toJune 30, 2025 filed with the ~~issuance~~SEC on August 5, 2025, and other documents filed with the SEC from time to time. ~~This~~Forward-looking ~~proposal~~statements ~~required~~represent the ~~affirmative~~Company’s ~~vote~~beliefs and assumptions only as of the ~~holders~~date of ~~ordinary~~this ~~shares~~Current ~~representing~~Report. atExcept ~~least~~as ~~75%~~required ofby law, the ~~votes~~Company ~~cast~~assumes onno ~~the~~obligation ~~matter~~to update these forward-looking statements publicly, or to beupdate ~~approved. The~~the reasons actual results ofcould differ materially from those anticipated in the ~~shareholders’~~forward-looking ~~vote~~statements, ~~were~~even asif ~~follows:~~new information becomes available in the future.

For	Against	Abstain	Broker Non-Votes
6,052,112	15,968,622	477,819	*

Item 9.01

Financial Statements and Exhibits.

~~Proposal No. 7~~(d) Exhibits: Equity Incentive Plan Proposal. The shareholders did not approve an amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan to increase the number of ordinary shares available for issuance thereunder by 4,000,000 ordinary shares. The results of the shareholders’ vote were as follows:

For	Against	Abstain	Broker Non-Votes
Exhibit		Description
2,462,277	11,258,350	589,480	8,188,446
5.1		Opinion of A&L Goodbody LLP
23.1		Consent of A&L Goodbody LLP (included in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* No broker non-votes arose in connection with Proposals 2, 4, 5 or 6, due to the fact each matter was considered "routine" under New York Stock Exchange rules. SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Iterum Therapeutics plc
Date:	September 10, 2025	By:	/s/ Corey N. Fishman
			Corey N. FishmanChief Executive Officer

ITERUM THERAPEUTICS PLC

Date: October 16, 2025

/s/ Corey N. Fishman

Corey N. Fishman

Chief Executive Officer

Filing Compare · Iterum Therapeutics plc